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Background: This research aimed to study the role of ezrin, CD44, and VEGF in invasion, metastasis, recurrence,
and prognosis of giant cell tumor of bone (GCTB) and its association with the clinical and pathological features of
GCTB.
Methods: Expression status of ezrin, CD44, and VEGF in 80 GCTB tissues and its adjacent noncancerous tissue
samples were measured with immunohistochemical and Elivison staining. Their correlation with the clinical and
pathologic factors was statistically analyzed by chi-square test.
Results: The expression status of ezrin, CD44, and VEGF were significantly higher in GCTB tissue samples than in
its adjacent noncancerous tissue samples and in GCTB at Campanacci stage III than in Campanacci stages I and II
(P < 0.05). No significant difference was found in age and sex of the patients and locations of the tumor (P > 0.05).
Survival analysis showed that the expression status of ezrin, CD44, VEGF, and Campanacci clinical stages of GCTB
were positively associated with the survival rate of GCTB patients and negatively associated with ezrin and
Campanacci stages of GCTB, indicating that ezrin, CD44, VEGF, and Campanacci clinical stages of GCTB are the
independent factors for GCTB.
Conclusions: Ezrin, CD44, and VEGF are over-expressed in GCTB tissue and its adjacent noncancerous tissue samples
and may play an important role in the occurrence, invasion, metastasis, and recurrence of GCTB. Measurement of ezrin,
CD44, and VEGF expression status may contribute to the judgment of prognosis of GCTB patients.
Keywords: Giant cell tumor of bone, Ezrin, CD44, VEGF, PrognosisBackground
Giant cell tumor of bone (GCTB), a primary tumor of
bone, frequently occurs in metaphysis of long bones, espe-
cially in the distal femur and proximal tibia [1,2]. It has a
high recurrence rate after surgery with involvement of
joints and their surrounding soft tissues and even causes
serious dysfunction. Sometimes, it also incurs lung metas-
tasis. At present, Campanacci imaging classification was
an accepted classification standard of GCTBs.
GCTB is a low-grade malignant tumor with invasive,
expansive, and destructive growth, and its biological* Correspondence: yangzuozhangsci@163.com
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unless otherwise stated.behavior and prognosis are uncertain. At present, the re-
lation between its particular gene expression and bio-
logical behavior is a hot research topic.
Ezrin is abnormally expressed in many tumor tissues
and affects cellular motility, proliferation, apoptosis, and
cycle and plays an important role in invasion and metas-
tasis of tumors. In recent years, it has attracted more at-
tention of researchers with more researches [3]. CD44 is
a kind of cell adhesion factors, and changes in its expres-
sion are related to the progression, invasion, and metas-
tasis of tumors and tumor-free survival rate of patients.
VEGF is an important predisposing factor for tumor
angiogenesis, promotes tumor cell proliferation, hydro-
lyzes basement membrane, and enhances vascular per-
meability through its specific binding with the receptor.
Therefore, ezrin, CD44, and VEGF were used as the re-
search targets in this study.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
















Recurrence or metastasis No 43
Yes 37
Zhang et al. World Journal of Surgical Oncology  (2015) 13:168 Page 2 of 7In this study, expression status of ezrin, CD44, and
VEGF were measured with immunohistochemical tech-
nique in GCTB tissue samples, association of ezrin,
CD44, and VEGF with clinical pathological characteris-
tics and prognosis of GCTB patients, and their role in
invasion, metastasis, and recurrence of GCTB was ana-




Paraffin-embedded tumor tissue samples were taken from
80 GCTB patients who underwent operation and treat-
ment from 1998 to 2010 in Yunnan Provincial Tumor
Hospital. We have received a consent obtained from
the patients and approval from the institutional review
board of Tumor Hospital of Yunnan Province. Paraffin-
embedded adjacent normal tissue samples collected 3 cmFigure 1 Expression of Ezrin in GCTB and normal tissues (IHC, ×400). (A) Lo
cytoplasm. (B) High expression of ezrin in GCTB tissue (+ +) mainly locatedor farther from the tumor at operation served as controls.
All samples were tested by two pathologists according to
the WHO diagnostic criteria. Of the 80 patients included
in this study, 45 were males and 35 were females aged 14
to 57 years (mean: 29.5 years). The tumor was located in
the femur of 28 patients, in the tibia of 19 patients, in the
humerus of 12 patients, in the fibula of 12 patients, and in
the radius of 9 patients. Of the 80 patients, 13 were classi-
fied as Campanacci grade I, 26 as Campanacci grade II, 41
as Campanacci grade III, 49 underwent intra-lesion curet-
tage (including 21 underwent autologous bone grafting,
15 allogeneic bone grafting, and 13 bone cement filling)
and 31 underwent tumor resection (including 5 under-
went allogenic bone transplantation, 23 artificial joint re-
placement, and 3 vascularized fibular grafting), 30 had
recurrence, and 7 had pulmonary metastasis after oper-
ation (Table 1). Five patients died of pulmonary metastasis
in within 2 years.
The patients were followed up by telephone or E-mail
for 60 months (range: 7 to 112 months). The following
parameters about each patient were recorded, including
the follow-up start date, tumor-free survival time of the
patients, and censored value which necessitates recording
the patients who failed to recover during the follow-up,
died of other causes, or still had no relapse or metastasis
at the end of follow-up.
Methods
Immunophenotypes of ezrin, CD44, and VEGF were
identified with the two-step immunohistochemical and
Elivison staining. First, the collected tissue samples were
embedded in paraffin and a volume fraction of 0.03 was
obtained by dewaxing and hydrating the tissue sections
which were incubated in H2O2 for 20 min in order
to block the endogenous peroxidase. The antigen was
repaired for 5 min in a microwave containing citrate
buffer solution and washed with distilled water and PBS,
respectively, for 5 min. Finally, the samples were incu-
bated in water bath at 37°C for 2 h after drop-adding the
1st antibody dilution (with the titers of the 3 typesw expression of ezrin in GCTB tissue (+) mainly located in the
in the cytoplasm. (C) No expression of ezrin in adjacent normal tissue.
Table 2 Expression of ezrin, CD44, and VEGF in different tissues
Sample Cases Ezrin CD44 VEGF
n −/+ ++ − + − +
GCTB 80 33 (41.2%) 47 (58.8%) 50 (62.5%) 30 (37.5%) 31 (38.7%) 49 (61.3%)
Normal tissues 80 71 (88.8%) 9 (11.2%) 70 (87.5%) 10 (12.5%) 59 (73.8%) 21 (26.2%)
P <0.001 0.003 <0.001
GCTB, giant cell tumor of bone; VEGF, vascular endothelial growth factor.
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(2 min at each time). The samples were then completely
flushed, counterstained with hematoxylin, washed with
water, dehydrated after treated with the DAB solution,
mounted on slides, and observed under a microscope.
After the slides were observed under microscope, ezrin
was mainly distributed in the cytoplasm as brown yellow
particles, according to the intensity of staining and the
number of positive cells. In accordance with Mathew’s
[4] and others’ classification standards, ‘−’ indicates no
expression, ‘+’ indicates that the number of expressed
positive cells is less than 50% or stained lighter, and ‘+ +’
indicates that more than 50% cells are expressed and
stained deep. The cells whose cytoplasm contains brown
granules are positive CD44 cells. The positive cell percent-
age for each section was calculated in five high-power
fields with (−) referring to 10% and (+) to more than 10%.
VEGF was mainly distributed in cell plasma and less dis-
tributed in cell membrane. Cell plasma or membrane with
brown granules was positive. The positive cell ratio of
negative cases was less than 10%, while the positive cell ra-
tio of positive cases was more than 10%.Figure 2 Expression of CD44 and VEGF in GCTB tissue (IHC, ×400). (A) CD4
expressed as brown granules in GVTB tissue; (C) CD44 was not expressed i
normal tissues.Statistical analysis
Statistical analysis was performed using the SPSS19.0
software package. The relation between ezrin, CD44,
VEGF, and clinicopathological factors for GCTB was an-
alyzed by χ2 test. The correlation between ezrin, CD44,
and VEGF was studied by Spearman correlation analysis.
Tumor-free survival curve was plotted for the survival time
of patients with the 90-month follow-up data according to
the different factors. In addition, Kaplan-Meier, log-rank,
and multivariate Cox regression analysis showed that the
expression status of ezrin, CD44, and VEGF in GCTB pa-
tients were significantly different (P < 0.05, P < 0.01). As the
reported expression status of ezrin is lower in normal tis-
sue than in GCTB tissue [5], the Campanacci stages I to III
of GCTB, recurrence or metastasis of GCTB, and
recurrence- and metastasis-free GCTB were compared.
Results
Ezrin, CD44, and VEGF immunohistochemical staining results
Ezrin was expressed mainly in the cytoplasm as brown
granules (Figure 1). Because there are few samples with
expression under 20%, we choose a 50% cutoff as high4 was expressed as brown granules in GCTB tissue; (B) VEGF was
n adjacent normal tissues; (D) VEGF was not expressed in adjacent
Table 3 Relation between ezrin, CD44, and VEGF
expressions in GCTB patients and their clinical
pathological features
Clinical parameter n Ezrin CD44 VEGF
−/+ ++ − ++ − ++
Sex
Male 45 20 25 31 14 18 27
Female 35 13 22 19 16 13 22
P 0.510 0.181 0.795
Age
≤30 33 15 18 22 11 13 20
>30 47 18 29 28 19 18 29
P 0.522 0.519 0.921
Site
Femur 28 12 16 21 7 11 17
Tibia 19 9 10 12 17 8 11
Humerus 12 5 7 6 6 6 6
Fibula 12 4 8 8 4 4 8
Radius 9 3 6 3 6 2 7
P 0.930 0.208 0.777
Stage
I 13 6 5 11 2 7 6
II 26 14 12 19 7 13 13
III 41 11 30 20 21 11 30
P 0.007 0.009* 0.025
Recurrence or metastasis
No 43 24 19 32 11 21 22
Yes 37 9 28 18 19 10 27
P 0.004 0.018 0.046
*Fisher’s exact test value: comparison of Campanacci stages I, II, and III. VEGF,
vascular endothelial growth factor.
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The high expression rates of ezrin were 41.2% (33/80)
and 58.8% (47/80), respectively, in GCTB tissue, while
its high expression rate was 11.2% (9/80) in adjacent
normal tissue (χ2 = 39.670, P < 0.001, Table 2).
CD44 was mainly expressed as brown granules in cell
plasma and membrane (Figure 2A). The high expression
rate of CD44 was 37.5% (30/80) and 12.5% (10/80), re-
spectively, in GCTB tissue and its adjacent normal tissue
(χ2 = 13.333, P = 0.003, Table 2).
The high VEGF expressions were brown granules lo-
cated mainly in cell plasma and partially in the endothelial
cytoplasm. The extracellular matrix was weakly expressed
(Figure 2B). The VEGF high expression rate was 61.3%
(49/80) in GCTB tissue and 26.2% (21/80) in adjacent nor-
mal tissues (χ2 = 19.911, P < 0.001, Table 2).
Correlation between expressions levels of ezrin, CD44,
and VEGF in GCTB patients
The high expression rate of ezrin, CD44, and VEGF
was 58.8% (47/80), 37.5% (30/80), and 61.3% (49/80), re-
spectively, in GCTB patients. Spearman rank correlation
analysis showed that the ezrin and CD44 coefficient
(r= 0.597, P < 0.001), ezrin and VEGF coefficient (r = 0.741,
P < 0.001), and VEGF and CD44 coefficient (r = 0.616,
P < 0.001) were positively correlated.
Relation between ezrin, CD44, and VEGF expression in
GCTB patients and their clinical data
The expression status of ezrin, CD44, and VEGF were
not related with gender and age of GCTB patients and
the location of GCTB (P > 0.05, Table 2), while it was re-
markably higher in GCTB patients with recurrence and
metastasis than in those without recurrence and metas-
tasis (P < 0.05, Table 2). The high expression rate of
ezrin, CD44, and VEGF was higher in Campanacci
stages I to III of GCTB (P < 0.05, Table 3).
Survival analysis
Kaplan-Meier analysis and log-rank comparison showed
significant difference in tumor-free survival rates of
male and female GCTB patients aged ≤30 or >30 years
(P > 0.05). The tumor-free survival rates were signifi-
cantly higher for patients with GCTB at Campanacci
stages I and II than for those with GCTB at Campanacci
stage III (P < 0.01, Figure 3A) while the tumor-free survival
rate was obviously lower for ezrin (+ +) GCTB patients
than for ezrin (−/+) GCTB patients (P < 0.01, Figure 3B).
The tumor-free survival rate was significantly higher for
CD44 (−) GCTB patients than for CD44 (+) GCTB pa-
tients (P < 0.01, Figure 3C) while the tumor-free survival
rate was obviously lower for VEGF (+) GCTB patients than
for VEGF (−) GCTB patients (P < 0.05, Figure 3D).Multivariate Cox regression analysis showed that the
risk ratios for ezrin, CD44, VEGF, stage, age, site, and sex
were 3.027, 1.673, 0.684, 2.426, 0.612, 0.963, and 0.813, re-
spectively. The risk ratios for ezrin and Campanacci stage
were the relatively independent factors (P < 0.05, Table 4).
Discussion
Invasion, metastasis, and recurrence are major biological
and clinical characteristics of GCTB and the most import-
ant factors affecting the prognosis of GCTB patients. Inva-
sion, metastasis, and recurrence of tumor are a complex,
changeable, and multistep process, which can be affected
by many factors. In this study, the role of ezrin, CD44, and
VEGF in biological behaviors of GCTB and their applica-
tion was studied.
Ezrin, a link protein of cell membrane and cytoskel-
eton, can anchor actin in specific membrane, maintain
Figure 3 Survival curves of GCTB patients. (A) Campanacci stage (P = 0.002). (B) Expression of ezrin (P = 0.001). (C) Expression of CD44 (P = 0.003).
(D) Expression of VEGF (P = 0.021). Cum, cumulative.
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movement, interact with a variety of cell surface mole-
cules (CD44, Met, etc.) [6], regulate cell-cell adhesion
with cell-extracellular matrix, and promote metastasis
and proliferation of tumor cells. Ezrin can regulate cell
signal transduction by Rho factor, tyrosine kinase recep-
tor, and Ras-to-MAPK pathway and plays an important
role in cell movement, proliferation, apoptosis, cell cycle,
invasion, and metastasis of tumor cells [7-9]. In addition,
ezrin is related with micro-RNA and c-Myc [10,11]
where ezrin affects invasion and metastasis of tumors.It was reported that high ezrin expression levels play a
role in promoting invasion and metastasis of esophageal
carcinoma, breast cancer, ovarian cancer, liver cancer,
osteosarcoma, and other common tumors [7,8,12-15].
High ezrin expression status can induce conversion of a
variety of cell lines and abnormal proliferation [16].
Bruce et al. [5] analyzed the ezrin expression in more
than 5,000 tumor tissue specimens, including breast can-
cer, lung cancer, prostate cancer, colon cancer, sarcoma,
and their adjacent normal tissue samples with microarray
immunohistochemical method, showing that high ezrin
Table 4 Hazard of recurrence and metastasis in
association with multiple factors




Ezrin 3.027 1.030 ~ 8.895 0.044 0.550
CD44 1.673 0.692 ~ 4.046 0.253 0.451
VEGF 0.684 0.220 ~ 2.127 0.512 0.579
Stage 2.426 1.140 ~ 5.160 0.021 0.385
Age 0.612 0.303 ~ 1.236 0.171 0.359
Site 0.963 0.752 ~ 1.234 0.766 0.126
Sex 0.813 0.411 ~ 1.606 0.551 0.347
VEGF, vascular endothelial growth factor.
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grade of sarcoma and recurrence of breast cancer.
Our study showed that the high ezrin expression rate
was significantly higher in GCTB tissue than in its adja-
cent normal tissue (58.8% vs 11.2%, P < 0.05). The high
ezrin expression rate gradually increased in Campanacci
stages I to III of GCTB and was significantly different
between Campanacci stage III and stages I to II of
GCTB. The ezrin expression status was significantly
higher in GCTB patients with recurrence and metastasis
than in those without recurrence and metastasis, indicat-
ing that ezrin expression status is higher in GCTB pa-
tients and may influence the biological behaviors of
GCTB, such as invasion, recurrence, and metastasis.
Survival analysis of the follow-up data showed that
ezrin induced the GCTB biological behaviors, suggesting
that recurrence of GCTB is not related with the age and
gender of GCTB patients and tumor-free survival rate is
significantly lower for ezrin (+ +) GCTB patients than
for ezrin (−, +) GCTB patients. The median recurrence
and metastasis time of GCTB patients with a high ezrin
expression status was 32 months. The median recur-
rence and metastasis of GCTB patients with a low ezrin
expression was longer than that (90 months) in our
study (P < 0.05). Kaplan-Meier analysis and log-rank
comparison showed that high ezrin expression status in
GCTB patients was closely related with invasion, metas-
tasis, and recurrence of GCTB after operation.
CD44, a receptor of hyaluronic acid and a marker of
tumor stem cells, is a kind of cell adhesion factors.
Changes in its expression are related to the progression,
invasion, and metastasis of GCTB and the tumor-free sur-
vival rate of GCTB patients. CD44 and its ligand hyaluro-
nan are widely distributed in human body, and its binding
to hyaluronic acid caused by abnormal expression of
CD44 may influence the occurrence and development
of tumors [17]. CD44 is involved in cell adhesion and mi-
gration, lymphocyte activation, extracellular matrix accu-
mulation, and metastasis of tumor cells [18]. Elliott et al.
[11] showed that ezrin may play an important role intumorigenesis by regulating cell adhesion molecules. Ezrin
can directly interact with the cytoplasm of CD44 mole-
cules, influence conformation of cytoskeletal protein and
its distribution, change apoptosis of tumor cells, regulate
cell-cell adhesion with extracellular matrix, and promote
metastasis and proliferation of tumors. In this study,
CD44 was abnormally expressed in GCTB patients. The
higher the Campanacci stage was, the higher the positive
CD44 expression rate was. Moreover, survival analysis
showed that CD44 could affect the recurrence of GCTB,
and its expression was positively related to that of ezrin,
indicating that the expression of CD44 is related to the oc-
currence, development, and infiltration of GCTB.
Kumta et al. [19] detected the expression of VEGF in
14 GCTB patients by semiquantitative RT-PCR and im-
munohistochemistry, respectively, showing that multiple
subtypes of VEGF, especially 121 subtypes, are highly
expressed in GCTB patients and the expression of VEGF
is related to the osteolytic destruction and local recur-
rence of GCTB. In this study, the high expression rate of
VEGF was significantly higher in GCTB tissues than in
its adjacent normal tissues (61.3% vs 26.2%). In addition,
the VEGF expression status was higher in GCTB pa-
tients at Campanacci stage III with recurrence and me-
tastasis than in those at Campanacci stages I and II with
no recurrence and metastasis. The results of our study
agreed with those of Kumta [19]. However, the mechan-
ism of VEGF is not fully understood. Knowles et al. [20]
showed that hypoxia can induce the expression of
hypoxia-inducible factor (HIF) and regulate the expres-
sion of VEGF by autocrine and paracrine which indir-
ectly affect the formation of osteoclasts. Matsumoto
et al. [21] reported that the VEGF-Flt-1-FAK pathways
consisting of VEGF and its receptor are involved in aggre-
gation and proliferation of osteoclast precursor cells and
the bone destruction. Furthermore, the expression of ezrin
and VEGF in GCTB patients was positively correlated
with the correlation coefficient (r = 0.741, P < 0.001) in this
study. Youn [22] showed that ezrin can enhance VEGF-
induced nitric oxide production by activating calpain,
thereby regulating the function of endothelial cells and
vascular generation, suggesting that VEGF may play a role
in the recurrence and metastasis of GCTB, and interact
with ezrin.
Conclusions
In conclusion, ezrin is abnormally expressed in GCTB
patients and is related with the invasion, metastasis, and
recurrence of GCTB. The expression of ezrin, CD44,
and VEGF is related with GCTB. Ezrin, CD44, and
VEGF may play an important role in the occurrence,
development, invasion, metastasis, and recurrence of
GCTB and can thus be used as significant predictors
for the biological behaviors and prognosis of GCTB
Zhang et al. World Journal of Surgical Oncology  (2015) 13:168 Page 7 of 7patients. However, further Cox multivariate regression
analysis revealed that only ezrin and stage were the rela-
tively independent impact factors, implying that the role
of ezrin and stage are relatively important. Invasion,
metastasis, and recurrence of tumors are extremely
complex, as they are not caused by one or two factors.
Operation methods and ideas of doctors have certain ef-
fects on the recurrence or metastasis of GCTB [23].
Therefore, the relation between ezrin and biological be-
haviors of GCTB needs to be verified in more experi-
ments. Research on ezrin, CD44, and VEGF and their
correlation with tumor prognosis will help to further re-
veal the underlying mechanism of the invasion and me-
tastasis of GCTB and prognosis of GCTB patients.
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